221 related articles for article (PubMed ID: 34748189)
1. Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease.
Lenders M; Brand E
Drugs; 2021 Nov; 81(17):1969-1981. PubMed ID: 34748189
[TBL] [Abstract][Full Text] [Related]
2. Update on role of agalsidase alfa in management of Fabry disease.
Ramaswami U
Drug Des Devel Ther; 2011 Mar; 5():155-73. PubMed ID: 21552486
[TBL] [Abstract][Full Text] [Related]
3. Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy.
Laffer B; Lenders M; Ehlers-Jeske E; Heidenreich K; Brand E; Köhl J
Front Immunol; 2024; 15():1307558. PubMed ID: 38304433
[TBL] [Abstract][Full Text] [Related]
4. Generation and Characterization of a Polyclonal Human Reference Antibody to Measure Anti-Drug Antibody Titers in Patients with Fabry Disease.
Lenders M; Scharnetzki D; Heidari A; Di Iorio D; Wegner SV; Brand E
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800950
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease.
Hughes D; Gonzalez D; Maegawa G; Bernat JA; Holida M; Giraldo P; Atta MG; Chertkoff R; Alon S; Almon EB; Rocco R; Goker-Alpan O
Genet Med; 2023 Dec; 25(12):100968. PubMed ID: 37634127
[TBL] [Abstract][Full Text] [Related]
6. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Wallace EL; Goker-Alpan O; Wilcox WR; Holida M; Bernat J; Longo N; Linhart A; Hughes DA; Hopkin RJ; Tøndel C; Langeveld M; Giraldo P; Pisani A; Germain DP; Mehta A; Deegan PB; Molnar MJ; Ortiz D; Jovanovic A; Muriello M; Barshop BA; Kimonis V; Vujkovac B; Nowak A; Geberhiwot T; Kantola I; Knoll J; Waldek S; Nedd K; Karaa A; Brill-Almon E; Alon S; Chertkoff R; Rocco R; Sakov A; Warnock DG
J Med Genet; 2024 May; 61(6):520-530. PubMed ID: 37940383
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies.
Tuttolomondo A; Simonetta I; Riolo R; Todaro F; Di Chiara T; Miceli S; Pinto A
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576250
[TBL] [Abstract][Full Text] [Related]
8. Effects of switching from agalsidase-α to agalsidase-β on biomarkers, renal and cardiac parameters, and disease severity in fabry disease forming neutralizing antidrug antibodies: a case report.
Shima H; Tsukimura T; Shiga T; Togawa T; Sakuraba H; Doi T; Ikeda Y; Okamoto T; Yoshikawa Y; Kimura T; Iwase T; Inoue T; Tashiro M; Okada K; Minakuchi J
CEN Case Rep; 2023 Dec; ():. PubMed ID: 38135868
[TBL] [Abstract][Full Text] [Related]
9. Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data.
Feriozzi S; Chimenti C; Reisin RC
Drug Des Devel Ther; 2024; 18():1083-1101. PubMed ID: 38585254
[TBL] [Abstract][Full Text] [Related]
10. Development of Lanzyme as the Potential Enzyme Replacement Therapy Drug for Fabry Disease.
Deng M; Zhou H; Liang Z; Li Z; Wang Y; Guo W; Zhao AY; Li F; Mu Y; Zhao AZ
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671438
[TBL] [Abstract][Full Text] [Related]
11. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study.
Linhart A; Dostálová G; Nicholls K; West ML; Tøndel C; Jovanovic A; Giraldo P; Vujkovac B; Geberhiwot T; Brill-Almon E; Alon S; Chertkoff R; Rocco R; Hughes D
Orphanet J Rare Dis; 2023 Oct; 18(1):332. PubMed ID: 37865771
[TBL] [Abstract][Full Text] [Related]
13. Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY.
Mauhin W; Lidove O; Amelin D; Lamari F; Caillaud C; Mingozzi F; Dzangué-Tchoupou G; Arouche-Delaperche L; Douillard C; Dussol B; Leguy-Seguin V; D'Halluin P; Noel E; Zenone T; Matignon M; Maillot F; Ly KH; Besson G; Willems M; Labombarda F; Masseau A; Lavigne C; Froissart R; Lacombe D; Ziza JM; Hachulla E; Benveniste O
Orphanet J Rare Dis; 2018 Jul; 13(1):127. PubMed ID: 30064518
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Clinical-Pathologic Results of Enzyme Replacement Therapy in Prehypertrophic Fabry Disease Cardiomyopathy.
Frustaci A; Verardo R; Galea N; Alfarano M; Magnocavallo M; Marchitelli L; Sansone L; Belli M; Cristina M; Frustaci E; Russo MA; Chimenti C
J Am Heart Assoc; 2024 Apr; 13(8):e032734. PubMed ID: 38563373
[TBL] [Abstract][Full Text] [Related]
15. Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease.
Deng M; Zhou H; He S; Qiu H; Wang Y; Zhao AY; Mu Y; Li F; Zhao AZ
Orphanet J Rare Dis; 2023 Sep; 18(1):275. PubMed ID: 37670350
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of anti-drug antibodies and disease-specific biomarkers in three patients from a Japanese Fabry family treated with enzyme replacement therapy.
Kubota T; Tsukimura T; Shiga T; Togawa T; Sakuraba H
CEN Case Rep; 2023 May; 12(2):171-175. PubMed ID: 36205882
[TBL] [Abstract][Full Text] [Related]
17. Is just enzyme replacement therapy enough for Fabry disease treatment? Have we missed a trick?
Ozer H; Baloglu I; Topkac A; Ozturk Y; Yonet F; Daglı F; Kilinc İ; Turkmen K
Nefrologia (Engl Ed); 2024; 44(2):217-223. PubMed ID: 37179210
[TBL] [Abstract][Full Text] [Related]
18. First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland.
Nowicki M; Komar M; Kusztal M; Mizia-Stec K; Liberek T; Małyszko J; Muras-Szwedziak K; Pawlaczyk K; Podolec P; Sławek J
F1000Res; 2021; 10():841. PubMed ID: 34745562
[TBL] [Abstract][Full Text] [Related]
19. Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders.
Seras-Franzoso J; Díaz-Riascos ZV; Corchero JL; González P; García-Aranda N; Mandaña M; Riera R; Boullosa A; Mancilla S; Grayston A; Moltó-Abad M; Garcia-Fruitós E; Mendoza R; Pintos-Morell G; Albertazzi L; Rosell A; Casas J; Villaverde A; Schwartz S; Abasolo I
J Extracell Vesicles; 2021 Mar; 10(5):e12058. PubMed ID: 33738082
[TBL] [Abstract][Full Text] [Related]
20. Fasudil alleviates the vascular endothelial dysfunction and several phenotypes of Fabry disease.
Choi JB; Seol DW; Do HS; Yang HY; Kim TM; Byun YG; Park JM; Choi J; Hong SP; Chung WS; Suh JM; Koh GY; Lee BH; Wee G; Han YM
Mol Ther; 2023 Apr; 31(4):1002-1016. PubMed ID: 36755495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
